medigraphic.com
ISSN 1561-297X (Print)

2011, Number 1

<< Back Next >>

Rev Cubana Estomatol 2011; 48 (1)

Oncocyte variant of mucoepidermoid carcinoma

Salazar RS; Jiménez GJJ; Suárez LA; Martin MLA

Language: Spanish
References: 26
Page: 62-68
PDF size: 175.94 Kb.


ABSTRACT

The mucoepidermoid carcinoma is the commonest of all malignant tumors of salivary glands, accounting for the 30 % of them. Approximately the half of cases (53 %) occurs in the major salivary glands. The 45 % has predominance in parotid gland, the 7 % in the submandibular one, and the 1 % in the sublingual gland one. This type of tumor is more frequent in female sex (3-2) and at fifth decade of life. Multiple variants with different ranks have been described including the oncocyte, sclerosant, unicystic, sebaceous, of clear cells, high degree spherical cells, fusocellular and psammomatous. The mucoepidermoid carcinoma, oncocyte variant, is an unusual subtype that may to shows significant oncocyte changes. Authors report a case of histological high degree mucoepidermoid carcinoma. The rate of Ki 67 was of 5 %, the negative tumor for C-erb2 and had immunoreaction to Ecaderine and Syndecan-1.


REFERENCES

  1. Goode RK, El-Naggar AK. Mucoepidermoid carcinoma. Pathology and Genetics of Head and Neck Tumours. Lyon: IARC Press; 2005.

  2. Kwon H, Lim W, Choi Y, Nam J, Han C, Kim J, et-al. High-grade oncocytic mucoepidermoid carcinoma of the minor salivary gland origin: a case report with immunohistochemical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(6):72-7.

  3. Veras EF, Sturgis E, Luna MA. Sclerosing mucoepidermoid carcinoma of the salivary glands. Ann Diagn Pathol. 2007;11(6):407-12.

  4. Jahan-Parwar B, Huberman RM, Donovan DT, Schwartz MR, Ostrowski ML. Oncocytic mucoepidermoid carcinoma of thesalivary glands. Am J Surg Pathol. 1999;23:523-9.

  5. Brandwein-Gensler M, Hille J, Gnepp D, Urken M, Ivanov K. The many faces of mucoepidermoid carcinoma. Pathol Case Rev. 2000;5:214-20.

  6. Hamed G, Shmookler BM, Ellis GL, Punja U, Feldman D. Oncocytic mucoepidermoide carcinoma of the parotid gland. Arch Pathol Lab Med.1994;118(3):313-4.

  7. Sidhu GS, Waldo ED. Oncocytic change in mucoepidermoidcarcinoma of the parotid gland. Arch. Pathol. 1975;99(83):663-6.

  8. Lopez-Terrada D, Bloom MG, Cagle PT, Ostrowski ML. Oncocytic mucoepidermoid carcinoma of the trachea. Arch Pathol Lab Med. 1999;123:635-7.

  9. Leocata P, Villari D, Fazzari C, Lentini M, Fortunato C, Nicotina PA. Syndecan-1 and Wingless-type protein-1 in human ameloblastomas. J Oral Pathol Med. 2007;36:394-9.

  10. Okabe M, Inagaki H, Murase T, Inoue M, Nagai N, Eimoto T. Prognostic significance of p27 and Ki-67 expression in mucoepidermoid carcinoma of the intraoral minor salivary glands. Mod Pathol. 2001;14:1008-14.

  11. Ma Y, George J, Dietz-Band J, James W, Slamon DJ, Batsakis JG. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res. 1994;54:5675-82.

  12. Rosa JC, Felix A, Fonseca I. Soares J Immunoexpression of c-erbB-2 and p53 in benign and malignant salivary neoplasms with myoepithelial differentiation. J Clin Pathol. 1997;50:661-3.

  13. Giannoni C, El Naggar AK, Ordonez NG, Tu ZN, Austin J, Luna MA. C-erbB- 2/neu oncogene and Ki-67 analysis in the assessment of palatal salivary gland neoplasms. Otolaryngol Head Neck Surg. 1995;112:391-8.

  14. Luna M. Salivary mucoepidermoid carcinoma: revisited. Adv Anat Pathol. 2006;13:293-307.

  15. Kyndi M, Sorensen FB, Knudsen H. Estrogen receptor, progesterone receptor, HER-2, and response to post mastectomy radiotherapy inhigh-risk breast cancer: The Danish Breast Cancer Cooperative Group. J Clin Oncol. 2006;26:1419-26.

  16. Francis GD, Dimech M, Giles L. Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: Results of the RCPA Quality Assurance Program. J Clin Pathol. 2007;60:1277-83.

  17. Evans HL. Mucoepidermoid carcinoma of salivary glands: astudy of 69 cases with special attention to histologic grading. Am J Clin Pathol. 1984; 81:696-701.

  18. Brannon RB, Willard CC. Oncocytic mucoepidermoid carcinomaof parotid gland origin. Oral Surg, Oral Med, Oral Pathol, Oral Radiol Endod. 2003;96:727-33.

  19. Goode RK, Auclair PL, Ellis GL. Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria Cancer. 1998;82:1217-24.

  20. Monoo K, Sageshima M, Ito E, Nishihira S, Ishikawa K. Histopathological grading and clinical featuresof patients with mucoepidermoid carcinoma of the salivary glands. NipponJibiinkoka Gakkai Kaiho. 2003;106:192-8.

  21. Heavner SB, Shah RB, Moyer JS. Sclerosing mucoepidermoid carcinoma of the parotid gland. Eur Arch Otorhinolaryngol. 2006; 263:955-9.

  22. Ro Y, Muramatsu T, Shima K. Correlation between reduction of syndecan-1 expression and clinico-pathological parameters in squamous cell carcinoma of tongue. Int J Oral Maxillofac Surg. 2006;35:252-7.

  23. Kurokawa H, Zhang M, Matsumoto S, Yamashita Y, Tanaka T, Takamori K. Reduced syndecan-1 expression is correlated with the histological grade of malignancy at the deep invasive front in oral squamous carcinoma. J Oral Pathol Med. 2006;35:301-6.

  24. Andreadis D, Epivatianos A, Mireas G, Nomikos A, Poulopoulos A, Yiotakis J, etal. Immunohistochemical detection of E-cadherin in certain types of salivary gland tumours. J Laryngol Otol. 2006;120(4):298-304.

  25. Bologna-Molina R, Mosqueda-Taylor A, Lopez-Corella E, Paes de Almeida O, Farfán-Morales JE, Molina-Frechero N, et-al. Comparative expression of syndecan-1 and Ki-67 in peripheral and desmoplastic ameloblastomas and ameloblastic carcinoma. Pathology International. 2009;59:229-33.

  26. Bologna-Molina R, Mosqueda-Taylor A, Lopez-Corella E. Syndecan-1 (CD138) and Ki-67 expression in different subtypes of ameloblastomas. Oral Oncol. 2008;44:805-11.




2020     |     www.medigraphic.com